This study demonstrates that HOPE significantly reduces early allograft dysfunction (13% in the HOPE group vs. 35% in the SCS group, p = 0.007), indicating improved graft viability and function. HOPE-treated livers also exhibited better one-year graft survival (p = 0.03) and a lower need for re-transplantation (0% vs. 11%, p = 0.03). Furthermore, patients in the HOPE group had fewer cardiovascular complications (p = 0.04) and lower readmission rates at six months (20% vs. 38%, p = 0.04). These results suggest that implementing HOPE as a standard preservation method for ECD liver grafts may enhance transplant outcomes and improve patient prognosis.
Ravaioli M, Germinario G, Dajti G, et al. Hypothermic oxygenated perfusion in extended criteria donor liver transplantation-A randomized clinical trial. Am J Transplant. 2022;22(10):2401-2408. doi:10.1111/ajt.17115
